Vivos Therapeutics Inc VVOS

Healthcare

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.

NDAQ:VVOS - Post by User

Vivos Therapeutics Inc > VVOS.....Early a.m runner on NR

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Sep 18, 2024 9:28am

31 Views

Post# 36228721

VVOS.....Early a.m runner on NR

You might think the volume & price action is related to this a.m's NR.....

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

2024-09-18 04:00 ET - News Release

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model

Vivos’ DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17

LITTLETON, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of proprietary treatments for sleep related breathing disorders (SRBDs), including obstructive sleep apnea (OSA), today announced receipt of what is believed to be the first ever U.S. Food and Drug Administration (FDA) 510(k) clearance to treat moderate to severe OSA and snoring in children using Vivos’ proprietary flagship oral medical device.

But I would have to say that this is the main reason for todays activity is A good ol "Pre-funded Warrant" dumping on the unsuspecting Chasers....read this ; )

sec.gov/Archives/edgar/data/1716166/000149315224030832/form424b1.htm